We are an NHS funded not-for-profit organisation that supports quality, optimised prescribing for patients.

We produce evidence-based resources and tools for primary care commissioners, and provide a platform to share innovation across the NHS.

Most of our materials are publicly available, however we also provide a range of data and intelligence tools, webinars and events for our subscribers.

We also aim to engage with a broad range of stakeholders including patients and carer groups, the pharmaceutical industry and voluntary sector organisations.

  • Latest news

    Read all our latest news and updates

    All News
  • 11 October 2018

    Behavioural Change Webinar sessions - 29th Nov, 13th Dec, 7th Jan & 24th Jan, 1pm - 2pm

    The 4 behavioural change webinars, presented by Dr Rowena Merrit and John Bromley from The National Social Marketing Centre, will begin by looking at how to deliver a social marketing/behaviour change project on a limited budget.

    The 4 behavioural change webinars, presented by Dr Rowena Merrit and John Bromley from The National Social Marketing Centre, will begin by looking at how to deliver a social marketing/behaviour change project on a limited budget.

    Read more >
  • 30 August 2018

    Bulletin 226 launched - Medicines in schools

    Commissioners can use these resources to support developing a medicines policy in schools.

    Commissioners can use these resources to support developing a medicines policy in schools. The resource covers both prescribed medicines and the use of OTC medicines without the need for a prescription. Parent consent form templates are available and can be adapted for local use.

    Read more >
  • 23 August 2018

    Bulletin 156 launched - Commissioning high cost drugs and devices

    This bulletin provides background and guidance to commissioners on arrangements for high cost drugs and devices that are excluded from the National Tariff and provides supporting tools for implementation.

    This bulletin provides background and guidance to commissioners on arrangements for high cost drugs and devices that are excluded from the National Tariff and provides supporting tools for implementation.

    Read more >
Loading...